SCHEMBL3016734

SCHEMBL3016734

Cc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4c(F)cccc4F)CC3)n2)c1C

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.40
NPC1 O15118 5/20 0.37
RAB9A P51151 5/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35
MAPK1 P28482 2/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
APLNR P35414 1/20 0.34
DNM1L O00429 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
CXCR2 P25025 1/20 0.32
FAAH O00519 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012220 0.93 AR (0.41) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3016534 0.93 LMNA (0.34) ARNPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL3018421 0.90 DNM1L (0.35) NPC1RAB9ASMN1; SMN2MAPK1LMNA
SCHEMBL3022758 0.89 AR (0.42) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL3006144 0.89 NR3C1 (0.37) NPC1RAB9ASMN1; SMN2MAPK1LMNA
SCHEMBL3001734 0.88 SMN1; SMN2 (0.40) NPC1RAB9ASMN1; SMN2MAPK1LMNA
SCHEMBL3014739 0.87 F2RL3 (0.32) ARNPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL3015242 0.87 AR (0.39) ARNPC1RAB9ASMN1; SMN2PKM
SCHEMBL2999503 0.87 GPR6 (0.37) NPC1RAB9ASMN1; SMN2MAPK1LMNA
SCHEMBL3013735 0.86 GPR6 (0.39) NPC1RAB9ASMN1; SMN2MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885NPC1 15/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.